Načítá se...
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
BACKGROUND: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effectiv...
Uloženo v:
| Vydáno v: | EBioMedicine |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6441848/ https://ncbi.nlm.nih.gov/pubmed/30662002 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.01.019 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|